Advance your academic career, collaborate globally, and expand your network— join now !

Joan Carles Escolà-Gil

Dr. Joan Carles Escolà-Gil

Institut d’Investigacions Biomèdiques (IIB) Sant Pau

Share Link

Share

Information

Dr. Joan Carles Escolà-Gil currently works as a Senior Researcher at the Institut de Recerca Sant Pau, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain. He is also a Collaborating Professor at the Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona. He was a visiting professor at the Wihuri Research Institute in 2010 and a visiting professor at the Finnish Institute for Health and Welfare, Helsinki, Finland, in 2015. He graduated from the University of Barcelona in 1991. As a principal investigator, his main line of research focuses on the development and metabolic characterization of genetically modified mice as models of dyslipidemia (and more specifically, HDL alterations), obesity, diabetes, and arteriosclerosis. In addition, he also works on projects focused on the study and clinical, biochemical, and genetic characterization of patients with metabolic alterations that pose a cardiovascular risk, especially dyslipidemia. This line is more closely linked to clinical research linked to healthcare activity.

Research Keywords & Expertise

Atherosclerosis
Cancer Biology
Cardiovascular Disease
Diabetes
lipoproteins

Fingerprints

49%
lipoproteins
47%
HDL
28%
LDL
23%
Atherosclerosis
17%
Cardiovascular Disease
10%
Diabetes

Short Biography

Dr. Joan Carles Escolà-Gil currently works as a Senior Researcher at the Institut de Recerca Sant Pau, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain. He is also a Collaborating Professor at the Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona. He was a visiting professor at the Wihuri Research Institute in 2010 and a visiting professor at the Finnish Institute for Health and Welfare, Helsinki, Finland, in 2015. He graduated from the University of Barcelona in 1991. As a principal investigator, his main line of research focuses on the development and metabolic characterization of genetically modified mice as models of dyslipidemia (and more specifically, HDL alterations), obesity, diabetes, and arteriosclerosis. In addition, he also works on projects focused on the study and clinical, biochemical, and genetic characterization of patients with metabolic alterations that pose a cardiovascular risk, especially dyslipidemia. This line is more closely linked to clinical research linked to healthcare activity.